Total: $519.8M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised ($M)*

Investors; Placement Agents; Details(Date)@

Aeterna Laboratories Inc. (Canada;TSE:AEL)

Bought deal

0.16S

C$2.1 (US$1.4)

Aeterna raised an additional C$2.1M (US$1.4M)from 5/00 bought deal through the underwriters'exercise of an overallotment option for 0.16M shares at C$13.25 (US$9.04) per share; the syndicate was led by Yorkton Securities Inc. and included HSBC Securities Inc., Canaccord Capital Corp., BLC Securities Inc. and Desjardins Securities Inc. (7/25)

Advanced Polymer Systems Inc.(APOS)

Sale of product lines and technology rights

--

$25

Advanced Polymer sold its cosmeceutical product lines and technology rights for certain topical pharmaceuticals to R.P. Scherer Corp. (subsidiary of Cardinal Health Inc. [NYSE:CAH]); Advanced Polymer received $25M up front and could receive an additional $26.5M in milestone payments over the next three years (7/26)

Antisoma plc; LSE:ASM)

Private placement of ordinary shares

7.68S

#9 (US$13.6)

Antisoma raised #9M (US$13.6M) by placing 7.68M ordinary shares at 117p (US$1.77) per share,a discount of approximately 8% to the closing middle market price on the London Stock Exchange on 7/26; Nomura International arranged the placement (7/27)

Aurora Biosciences Corp. (ABSC)

Sale of equity in another company

-

$1.7-

Aurora recognized a $1.7M gain as the result of the sale of its equity stake in Cytovia Inc. to Maxim Pharmaceuticals (MAXM), which in June acquired Cytovia in an all-stock transaction valued at more than $80M (7/20)

Avant Immuno therapeutics Inc.(AVAN)

Private placement of common stock

4.65S

$36.5

Avant raised $36.5M through a private placement of 4.65M shares at $7.85 per share (a 7.6% discount to the 7/14/00 closing price); PaineWebber Inc. served as placement agent (7/17)

Axys Pharmaceuticals Inc.(AXPH)

Private placement of common stock

1.639S

$10

Acqua Wellington North American Equities Fund agreed to purchase up to $50M of discounted Axys common stock over the next 15 months; the initial sale is of 1.639M shares at $6.10 each, for a total of $10M (7/21)

Bioject Medical Technologies (BJCT)

Private placement of common stock

1.3S

$10

Bioject sold 1.3M shares at $7.75 each for proceeds of $10M; Lone Pine Capital led the financing, and four other institutional investors participated (7/28)

Genelabs Technologies Inc.(GNLB)

Private placement of common stock

1S

$4

Acqua Wellington North American Equities Fund Ltd. agreed to buy up to $29M worth of Genelabs' common stock over the next 18 months; Acqua Wellington made an initial investment of $4M through a purchase of 1M shares at $4 per share (7/11)

Genome Therapeutics Corp.(GENE)

Sale of common stock through shelf registration

1.5S

$44.7

GTC sold 1.5M shares at a weighted average price of $31.01 under a 4/00 shelf registration that replaced a public offering attempt; Tucker Anthony Inc. acted as placement agent (7/10)

Ixion Biotechnology

Private placement of stock

3.34S

$6.7

Qvestor LLC, a U.S. subsidiary of Q-Med AB, purchased 3.34M shares of Ixion stock for $2 each for a total of $6.68M; Q-Med already had 0.56M shares of Ixion and had an option to acquire up to 50 percent of the company; after the closing, Q-Med owns 59 percent of Ixion (7/17)

La Jolla Pharmaceutical Co. (LJPC)

Private placement of common stock

4.8S

$29.4

La Jolla entered definitive agreements for the sale of 4.8M shares at $6.125 per share, for a total of $29.4M (7/19)

Matrix Pharmaceutical Inc. (MATX)

Private placement of common stock

2.5S

$31

Matrix entered definitive agreements to sell 2.5M shares at $12.50 per share (a discount of approximately 6% from the prior 20-day average trading Banc of America Securities LLC served as price); placement agent (7/13)

Meditech Pharmaceuticals Inc. (OTC BB:MDCH)

Common stock equity line

-

-

Meditech secured a $30M equity line from an undisclosed institutional investor (7/6)

Nabi(NABI)

Private placement of common stock

1.25S

$10

Nabi raised $10M through a private placement of an estimated 1.25M shares of common stock (based on the 7/13 closing price of $8.013 per share) (7/13)

Oncolytics Biotech Inc. (Canada; TSE:ONC)

Private placement of common stock

0.245S

C$3 (US$2.02)

Oncolytics sold 0.245M shares at C$12.25 (US$8.25) per share to Innovatech Grand Montreal (7/17)

Teva Pharmaceutical Industries Ltd.(Israel; TEVA)

Multicurrency five-year term loan credit facility

-

$135

Teva established a $135M multicurrency five-year term loan credit facility with a syndicate of banks, primarily based in Europe; the syndicate was arranged by The Sumitomo Bank Ltd. and Deutsche Bank AG and includes 12 other banks; Teva expected to fully draw down the facility within a month (7/17)

Theratechnologies (TSE:TH)

Exercise of warrants

0.208S

C$1.27 (US$0.85)

The Societe generale de financement du Quebec exercised 0.208M warrants at C$6.10 (US $4.12)per share, for proceeds of C$1.27M (US$0.85M);warrants were issued as part of a 6/99 financing (7/4)

United Therapeutics Corp. (UTHR)

Private placement of common stock

1.3S

$143

United raised $143M through the sale of 1.3M shares of common stock at $110 per share; Deutsche Banc Alex. Brown served as placement agent (7/13)

Xenova Group plc(XNVA)

Private placement of units

2.9U

#10 (US$14.9)

Xenova raised #10M (US$14.9M) by issuing 2.9M units at #3.45 (US$5.18); each unit consist of five new shares and four warrants at 85 pence each (exercisable between 1/1/01 and 10/31/01); Nomura International plc underwrote the issue (7/19)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Non-U.S. currencies converted at the exchange rate on the date of the announcement.

@ Dates refer to the date of the press release.

ASX = Australian Stock Exchange

LSE = London Stock Exchange

TSE = Toronto Stock Exchange

VSE = Vancouver Stock Exchange

OTC BB = Over The Counter Bulletin Board

No Comments